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Classical, genomic, thyroid hormone action
Thyroid hormone (TH) is essential for normal development, growth and metabolism. Its effects are mediated principally through triiodothyronine (T 3 ), which acts as a ligand for the TH receptors (TRs) β1, β2 and α1 [Harvey and Williams, 2002; Yen, 2001] . In the classical model of genes positively regulated by TH, the TR first binds as a heterodimer or homodimer on TH response elements (TRE) located in the promoter regions of target genes, where it interacts with corepressors.
Upon ligand binding, the TR homodimers are dissociated in favor of heterodimer formation with the retinoid-X receptor (RXR), resulting in release of the corepressors and recruitment of coactivators. This new complex attracts a large number of proteins which engage the RNA polymerase II in the transcription of the targeted gene ( Figure 1, part 1 ). This classical mechanism can also lead to increased expression of genes devoid of TREs, if they are target genes for transcription factors that are induced by this mechanism.
Nongenomic action of thyroid hormone
In addition to the classical, "nuclear" mode of TH action, a number of rapid effects taking place in the cytosol and at the plasma membrane have been subsequently identified. TH can control Ca 2+ entry, intracellular protein trafficking and regulation of protein kinase C [Davis and Davis, 2002; Davis et al., 2002] . The MAPK pathway can be activated by TH binding to the integrin αVβ3, located in the cell membrane, without entering the cell. This mechanism leads to phosphorylation of nuclear receptors and can induce angiogenesis and promote cell growth [Bergh et al., 2005; Tang et al., 2004] . A derivative of TH, 3-iodothyronamine (T 1 AM), can induce bradycardia and hypothermia within minutes through a mechanism that remains unknown [Scanlan et al., 2004] . These nongenomic actions of TH are mostly extranuclear, appear to be independent of TRs and have rapid effects on proteins rather than modulate gene expression.
Cytosolic activation of the PI3K pathway by TR
As all proteins, TRs are synthesized in the cytoplasm from where they are translocated into the nucleus to exert their genomic effect summarized above. A dynamic nucleo-cytoplasmic shuttling has been described [Baumann et al., 2001] . We recently identified a new mechanism of TH action in which the liganded TRβ interacts with the regulatory subunit of PI3K (p85α ) in the cytosol [Cao et al., 2005] (Figure 2 ). This leads to activation of PI3K ( Figure 2 ) and its downstream signaling cascade (Figure 1 part 2) , sequential phosphorylation and activation of the serine/threonine kinase Akt, mammalian target of rapamycin (mTOR) and its substrate p70 S6K . mTOR activation is rapid, with detectable phosphorylation as early as 10 minutes after T 3 treatment, and not sensitive to cycloheximide (CHX) treatment, indicating that this effect of TH uses preexisting proteins. TH acts through the TRβ, because in human fibroblasts that express the WT TRβ, introduction of a dominant negative mutant TRβ abrogated the effect of TH. Furthermore, a direct interaction between TRβ and PI3K could be demonstrated by coimmunoprecipitation of TRβ 1 with the p85α subunit of PI3K. However, activation of PI3K requires the presence of T 3 . The interaction between TRβ and PI3K most likely takes place in the cytosol. Within minutes after activation by T 3 , phosphorylated Akt, as part of the PI3K pathway, is translocated from the cytosol into the nucleus (Figure 1 part 2) . This TH action is very rapid and independent of protein synthesis, which is typical of nongenomic action. Yet, two aspects distinguish this mechanism of TH action from most other nongenomic effects of the hormone: 1) it requires TR binding and 2) its ultimate effect is 'genomic' with specific genes induced by this mechanism. For example, the calcineurin inhibitor ZAKI-4α had been previously described as a TH responsive gene [Cao et al., 2002; Cao and Seo, 2003; Miyazaki et al., 1996] . This effect was blocked by inhibitors of PI3K and by a dominant negative p85α subunit of PI3K [Cao et al., 2005] . Rapamycin, an inhibitor of mTOR also abrogated the TH-dependent induction of ZAKI-4α, suggesting the requirement of sequential activation of kinases initiated by the activation of PI3K. ZAKI-4α expression is also CHX sensitive, indicating that protein synthesis is necessary for the induction of ZAKI-4α. These results show that ZAKI-4α represents an example of an indirectly induced gene downstream of nongenomic action of TH. The transcription factor linking the PI3K pathway to ZAKI-4α expression has not yet been identified. A similar activation of PI3K has been observed for other steroid hormone nuclear receptors [Simoncini et al., 2000] . expression of more than 15,000 genes in fibroblasts of normal individuals by quantitative fluorescent cDNA microarray [Moeller et al., 2005b] . Fibroblasts from two subjects with resistance to thyroid hormone (RTH) due to mutations in the TRβ gene were used to confirm the specificity of the hormonal effect by the ability to discriminate between normal cells and cells with a defect in TH action. Microarray analysis identified 91 up-regulated and 5 down-regulated genes and confirmation by real-time PCR was obtained in 8 of 10 induced and 2 of 3 repressed genes that were tested. Several new TH responsive genes were identified, both positively (AKR1C1-3, PFKP, RAB3B, HIF-1α, COLVIA3) and negatively regulated (FGF7, ADH1B). Genes that had been found to respond to TH in other species were also found in these human cells (BTEB1, GLUT1, MCT4). Further evidence for T 3 -specific induction was provided by a graded dose response for induced genes that was absent in fibroblasts from the patients with RTH. Of special interest among the upregulated genes were the transcription factor subunit hypoxia-inducible factor (HIF)-1α, its target genes, glucose transporter (GLUT)1 and platelet-type phosphofructokinase (PFKP), and the monocarboxylate transporter (MCT)4. These genes are functionally related as they have important roles in cellular glucose metabolism, from glucose uptake (GLUT1) to glycolysis (PFKP) and lactate export (MCT4). The response of these genes to TH was reduced or absent in the TH resistant fibroblasts, which confirms the role of the TRβ.
TH target genes
The cytosolic action of TH induces HIF-1α and glycolytic genes
The transcription factor HIF-1 consists of two subunits, α and β. While the β subunit is constitutively expressed, the α subunit is tightly regulated. Cellular hypoxia leads to increase of HIF-1α protein levels by decreased ubiquitination [Semenza, 2001] and in normoxia, growth factors and hormones (e.g. EGF, IGF-1, insulin, androgens) lead to increased HIF-1α by posttranscriptional mechanisms [Bardos and Ashcroft, 2004; Kasuno et al., 2004] . The latter is mediated by cellular signal transduction pathways, especially the PI3K-Akt/PKB-mTOR pathway and the MAPK pathways [Fukuda et al., 2002; Kasuno et al., 2004] . We examined the involvement of the PI3K pathway by treating human skin fibroblasts with T 3 . In contrast to the response to growth factors, TH increased HIF-1α mRNA levels. mRNA of HIF-1α was increased after 3 hours and the effect lasted for the 24 hours of the experiments. mRNA induction led to significant increase in the protein, demonstrated by western blotting for HIF-1α as well as PFKP. Addition of the PI3K inhibitor LY294002 abrogated TH-dependent induction of mRNAs for HIF-1α as well as GLUT1, PFKP and MCT4 [Moeller et al., 2005a] . HIF-1α induction was direct and translation-independent, as CHX pretreatment did not inhibit HIF-1α mRNA increase after T 3 treatment. As expected, expression of HIF-1's target genes, GLUT1 and PFKP, was CHX-sensitive. The MAPK pathway was examined by pretreatment with PD98059, but inhibition of T 3 effect was not observed. The MAPK pathway seems not to be involved expression of these genes in human fibroblasts. These results further demonstrate that activation of the PI3K signaling pathway by TH and TRβ in the cytosol can lead to direct (HIF-1α) and indirect (GLUT1, PFKP, MCT4) gene expression.
Conclusion and perspective
Until recently, TH-mediated changes in gene expression were thought to be primarily, if not solely, initiated by direct nuclear TR binding to a TRE in the promoter of a target gene. We found that the same TRβ can also exert extranuclear actions. It is capable of activating cellular signaling pathways in the cytosol, as demonstrated for the PI3K pathway, which leads to induction of ZAKI4α, HIF-1α and its target genes. This cytosolic mechanism of TH-mediated TRβ-dependent action contributes to the overall effect of TH on gene expression. Surprisingly, some of the most highly induced genes in our experiments were later found to be downstream of the PI3K pathway (e.g. ZAKI-4α, PFKP). A possible explanation is that kinase cascades have the potential to amplify the signal from kinase to kinase, whereas on a TRE amplification steps are limited. The definition of the TRs therefore has broadened beyond being merely ligand-dependent nuclear transcription factors. We conclude that TH responsive genes can be directly induced by nuclear (e.g. BTEB1) and cytosolic action of TH (e.g. HIF-1α) without requirement of prior protein synthesis. Indirectly induced genes, following expression of a transcription factor, exist for both modes of TH action. We expect that more TH-responsive genes will be described as 'nongenomically' induced and that more signaling pathways will be found to be activated by the TRs.
